1	Image-based Explainable Artificial Intelligence Accurately Identifies				
2	Myelodysplastic Neoplasms Beyond Conventional Signs of Dysplasia				
3	Jan-Niklas Eckardt, ^{1,2} Ishan Srivastava, ^{1,2} Freya Schulze, ¹ Susann Winter, ¹ Tim Schmittmann, ³				
4	Sebastian Riechert, ^{2,3} Martin M. K. Schneider ¹ , Lukas Reichel, ¹ Miriam Eva Helena Gediga, ¹ Katja				
5	Sockel, ¹ Anas Shekh Sulaiman, ¹ Christoph Röllig, ¹ Frank Kroschinsky, ¹ Anne-Marie Asemissen, ⁴				
6	Christian Pohlkamp, ⁵ Torsten Haferlach, ⁵ Martin Bornhäuser, ^{1,6,7} Karsten Wendt, ^{2,3} and Jan Moritz				
7	Middeke ^{1,2}				
8 9	¹ Department of Internal Medicine I, University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany				
10 11	² Else Kröner Fresenius Center for Digital Health, TUD Dresden University of Technology, Dresden, Germany				
12 13	³ Institute of Software and Multimedia Technology, TUD Dresden University of Technology, Dresden, Germany				
14 15	⁴ Department of Hematology, Oncology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany				
16	⁵ Munich Leukemia Laboratory, Munich, Germany				
17 18	⁶ German Cancer Consortium (DKTK), Partner Site Dresden, and German Cancer Research Center (DKFZ), Heidelberg, Germany				
19	⁷ National Center for Tumor Diseases Dresden (NCT/UCC), Dresden, Germany				
20					
21	Running title: Deep learning detects MDS from bone marrow smears				
22	Corresponding author: Jan-Niklas Eckardt, MD, MSc, MHBA; Department of Internal Medicine I,				
23	University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Fetscherstraße 74,				
24	01307 Dresden, Germany; phone: +49 351 458 11542; e-mail: jan-niklas.eckardt@uniklinikum-				
25	<u>dresden.de</u>				
26	Key words: myelodysplastic neoplasms, deep learning, artificial intelligence, bone marrow				
27	Competing Interests: The authors declare no competing interests.				
28	text: 2190 words; abstract: 196 words; figures/tables: 3/3; supplementary figures/tables: 0/1;				
29	references: 62				

1

30 Abstract

31 Evaluation of bone marrow morphology by experienced hematologists is key in the diagnosis of 32 myeloid neoplasms, especially to detect subtle signs of dysplasia in myelodysplastic neoplasms 33 (MDS). The majority of recently introduced deep learning (DL) models in cytomorphology rely 34 heavily on manually drafted cell-level labels, a time-consuming, laborious process that is prone to 35 substantial inter-observer variability, thereby representing a substantial bottleneck in model 36 development. Instead, we used robust image-level labels for end-to-end DL and trained several state-37 of-the-art computer vision models on bone marrow smears of 463 patients with MDS, 1301 patients 38 with acute myeloid leukemia (AML), and 236 bone marrow donors. For the binary classifications of 39 MDS vs. donors and MDS vs. AML, we obtained an area-under-the-receiver-operating-characteristic 40 (ROCAUC) of 0.9708 and 0.9945, respectively, in our internal test sets. Results were confirmed in an 41 external validation cohort of 50 MDS patients with corresponding ROCAUC of 0.9823 and 0.98552, 42 respectively. Explainability via occlusion sensitivity mapping showed high network attention on cell 43 nuclei not solely of dysplastic cells. We not only provide a highly accurate model to detect MDS from 44 bone marrow smears, but also underline the capabilities of end-to-end learning to solve the bottleneck 45 of time-consuming cell-level labeling.

46

47 Introduction

48 Myelodysplastic neoplasms (MDS) encompass clonal myeloid malignancies that are characterized by 49 ineffective hematopoiesis, cytopenia, myelodysplasia, and recurrent genetic events.¹ The incidence of 50 MDS appears to be underestimated and incidence rates increase dramatically over the age of 70 years (up to an estimated 75:100,000 cases), representing a substantial societal burden in an aging 51 population.²⁻⁴ Although genetic findings are becoming increasingly important according to the new 52 53 WHO 2022 classification, accurate cytomorphologic evaluation of the bone marrow remains crucial 54 for the initial diagnosis, response assessment, and detection of disease transformation to acute myeloid 55 leukemia (AML).⁵ While counting myeloblasts is rather straightforward, signs of dysplasia are more 56 subtle and their accurate identification requires experienced investigators. Still, detection is often

57 challenging and prone to inter-observer variability, even for seasoned morphologists⁶⁻⁸, and shows
58 discrepancies between site and central review.⁹

59 In general, cytomorphologic evaluation of bone marrow aspirates in hematology remains essentially 60 unchanged over the last decades, as both preparation and evaluation are performed manually, 61 rendering the entire process time- and cost-intensive, as well as dependent on the experience and subjective judgement of the observer.¹⁰⁻¹² With the advent of deep learning (DL) systems for computer 62 63 vision¹³, a multitude of applications in the healthcare sector have been identified where DL is applied in image-based diagnostics.^{14,15} Convolutional neural nets (CNN), which consist of multiple artificial 64 65 neurons that are interconnected via convoluted deep layers, are commonly used for computer vision tasks.¹⁶ In cytomorphology, recent studies have utilized neural networks in order to correctly classify 66 peripheral blood and bone marrow cells based on their respective morphology¹⁷⁻²⁸, as well as to 67 accurately identify myeloid malignancies.^{29,30} 68

In this study, we used an end-to-end DL system to accurately differentiate between MDS, AML, and healthy donor bone marrow samples based on image-level labels, without the need for manually labeling cells or dysplastic morphologies.

72

73 Methods

74 Data sets

We identified 463 MDS patients that have been previously diagnosed and treated at the University Hospital Dresden, Germany. The first control group comprised 1301 AML patients that had been diagnosed and treated under the auspices of the multicenter German Study Alliance Leukemia (SAL) within the following previously reported multicenter trials: AML96³¹ [NCT00180115], AML2003³² [NCT00180102], AML60+³³ [NCT 00180167], and SORAML³⁴ [NCT00893373]. Patients were eligible upon diagnosis of MDS or AML according to the revised WHO/ICC criteria^{5,35}, age ≥ 18 years, and available biomaterial at initial diagnosis including bone marrow smears. The second

82 control group consisted of 236 bone marrow samples from healthy bone marrow donors who 83 underwent allogeneic bone marrow donation at our center as previously reported.³⁶ An additional 84 external validation cohort was obtained from the Munich Leukemia Laboratory (MLL), Munich, 85 Germany, consisting of 50 patients with diagnosed MDS according to the above-mentioned eligibility 86 criteria. Prior to analysis, written informed consent was obtained from all patients and donors 87 according to the revised Declaration of Helsinki.³⁷ All studies were approved by the Institutional 88 Review Board of the TUD Dresden University of Technology (EK 98032010 and EK 289112008).

89

90 **Image digitization**

91 Bone marrow smears (BMS) were prepared from anticoagulated bone marrow according to WHO 92 guidelines.³⁸ Staining of MDS, AML, and donor BMS was performed with the May-Grünwald-Giemsa method.¹¹ Image-level labels were derived from case-level diagnostics, including cytomorphology, 93 94 histology, cytogenetics and molecular genetics, previously documented for each case during routine 95 diagnostics or as part of the respective clinical trial. Using a Pannoramic 250 FLASH III 96 (3DHISTECH), we obtained high-resolution whole slide images. For every AML patient and bone 97 marrow donor, one image (50x magnification) per whole slide image was obtained using SlideViewer 98 (3DHISTECH). We assumed that subtle signs of dysplasia would not be fully captured in one field of 99 view alone. Therefore, for each MDS patient, we obtained four pictures (50x magnification) of 100 different areas of interest in the BMS.

101

102 Deep learning

103 End-to-end image-level prediction on bone marrow slides

We extended our previously described DL pipeline^{29,30} for binary image-level predictions for the delineation of MDS, AML, and healthy controls. Based on case-level diagnosis, images were labeled with either "MDS", "AML", or "healthy donor". Importantly, no cell-level manual labeling was performed. The pipeline was adapted to evaluate cases in a binary fashion, i.e. MDS vs. AML and

108 MDS vs. healthy donors. Potentially, imbalanced training data can bias a classifier towards the 109 predominant class. Considering the imbalances between the data sets (n=463 samples for MDS with 4 110 images per patient, resulting in 1852 MDS images in total; n=1301 samples for AML with 1 image per 111 patient; n=236 samples per donor with 1 image per donor), we used image augmentation techniques, 112 such as random sized cropping, color shifting and linear transformations, to balance the data sets for 113 each binary classification task. For all binary classifications, a 5-fold internal cross-validation was 114 used, i.e. a train-test-split of 80:20. Cases that were used for model training were strictly separated 115 from cases that were used for testing. In DL, determination of an optimal model cannot be done a 116 priori, but rather has to be evaluated given the specific use case, data set, and model architecture. 117 Hence, we evaluated six recently introduced DL architectures for computer vision including ResNet-118 $18/34/50/101/152^{39}$, ResNeXt-50 32x4d/101 32x8d⁴⁰, Wide-ResNet-50/101⁴¹, DenseNet- $121/161/169/201^{42}$, ShuffleNet v2 x0 5/v2 x1 02⁴³, and SqueezeNet v1.1⁴⁴. All DL models were pre-119 trained on ImageNet data.⁴⁵ The final architecture for each model was determined using automated 120 hyperparameter optimization with the Optuna framework.⁴⁶ DL models were implemented in Python 121 122 using the PyTorch framework. Computations were performed using the high-performance computing 123 (HPC) cluster of the TUD Dresden University of Technology.

124

125 **Performance evaluation**

Recall (*syn.*: sensitivity), precision (*syn.*: positive predictive value), and accuracy were used to evaluate classification performances. Recall is defined as the fraction of all positive predictions among all relevant events and precision is defined as the fraction of true positives among all positive predictions. Further, the area-under-the-curve (AUC) was determined for the receiver-operatingcharacteristic (ROC). All metrics are reported for each binary classification for the internal test sets as well as for the external validation cohort with 95% confidence intervals.

132

133 Explainability of classifications via occlusion sensitivity maps

To highlight network attention and thereby identify morphological cues the network used to delineate MDS, AML, and healthy donors, we used occlusion sensitivity maps (OSM). In OSM, random image areas are iteratively blocked from view of the CNN and classification performance is measured. If the blocked image area is highly relevant for accurate image-level classification, model performance will drop accordingly. This process is repeated for the entire image. Thus, image areas that are crucial for accurate predictions are highlighted so that morphologies that prompt the CNN classifier to predict a label can be evaluated and interpreted.

141

142 **Results**

143 End-to-end deep learning accurately delineates MDS from AML and healthy controls

144 Baseline characteristics of the MDS patient cohort are shown in Table 1. We evaluated six different neural network architectures³⁹⁻⁴⁴ for binary classification tasks iteratively. For the distinction between 145 MDS and healthy donors, we found Densenet-201⁴² to provide the highest classification performance, 146 147 with an accuracy of 0.97791 and a corresponding ROCAUC of 0.9708 (Table 2; Figure 1A). With respect to delineating MDS from AML, the best results were obtained using the Squeezenet⁴⁴ 148 149 architecture, resulting in an accuracy of 0.98072 and a ROCAUC of 0.9945 (Table 2; Figure 1B). 150 Detailed information on metrics and 95% confidence intervals of the best performing models for each 151 use-case is provided in Table 2. Individual model training on the HPC system for MDS vs. healthy 152 donors and MDS vs. AML took 20 hours each. An external validation set encompassing 50 MDS 153 patients was obtained from the Munich Leukemia Laboratory (MLL). Using our pre-trained models, 154 we achieved an accuracy of 0.9972 with a corresponding ROCAUC of 0.9823 in distinguishing 155 external MDS samples from healthy controls (Table 3, Figure 2A). With respect to delineating 156 external MDS samples from AML, an accuracy of 0.92104 was achieved with a ROCAUC of 0.98552 157 (Table 3, Figure 2B).

158

159 Explainable predictions via occlusion sensitivity maps

160 In order to make results interpretable to cytomorphologists, we used OSM that iteratively blocks 161 image areas from neural network evaluation and thus highlights (in red) image areas that are of high 162 importance for accurate predictions. In a proof-of-concept fashion, we found OSM to be cell-specific, 163 indicating that network attention is being focused on cells, rather than background or smudge. 164 Network attention was focused on cells in granulopoiesis and erythropoiesis and on megakaryocytes 165 (Figure 3). Interestingly, neural networks focused not only on signs of dysplasia, but also on cells we 166 deemed morphologically inconspicuous. High attention was given to defined signs of dysplasia 167 involving altered nuclear morphology such as chromatin clumping, dysfunctional segmentation, or 168 double nuclei. However, at times, high network attention was also given to cells with no apparent dysplasia as per conventional definition,^{11,47} while network attention in these cells was also mainly 169 170 focused on the nucleus, sometimes including the perinuclear zone. This indicates more intricate and 171 subtle morphological alterations unquantifiable by human observers. However, other signs of 172 dysplasia, such as hypogranulation, were disregarded by our model. This could possibly be either due 173 to confidence saturation - meaning the model found enough reasons in a given field of view to confidently predict MDS without paying attention to all apparent signs of dysplasia (defined or not) -174 175 or low-ranking signs of dysplasia that were not learned in the training process due to their limited 176 weight in making accurate predictions.

177

178 Discussion

179 Using end-to-end DL, we developed a software framework to distinguish between MDS, AML, and 180 healthy controls with very high accuracy based on BMS from 2000 individual patients and bone 181 marrow donors. Importantly, we have demonstrated that information abstraction even in MDS with 182 often subtle morphologies is feasible using end-to-end learning, in contrast to recent studies in hematology that primarily rely on the generation of cell-level labels.^{17–28,48,49} Using the latter approach, 183 184 a bottom-up system has to be devised where first thousands (usually hundreds of thousands) of labels 185 are required to build a robust classifier, and second individual cell-level predictions have to be 186 aggregated to generate a diagnosis-level prediction. Apart from being obviously time-consuming and

187 cost-ineffective, the generation of cell-level labels, i.e. the ground truth many classifiers in hematology currently are based on, is flawed due to substantial classification biases. For instance, Sasada et al.⁷ 188 189 evaluated divergence in cell classifications on 100,000 hematopoietic cells of 499 MDS patients. Up to 190 eleven experienced observers evaluated each cell image, however, only 55.6% of classifications were 191 found to match and especially low classification overlap was reported for dysplastic morphologies like hypo-granularity and Pseudo-Pelger-Huët anomaly.⁷ This bottleneck and pitfall of cell-level labeling 192 193 can essentially be bypassed by an end-to-end approach, such as ours. Our ground truth labels are not 194 derived from subjective observer judgment. Instead, they are established by routine diagnostics, 195 including cytomorphology, histology, flow cytometry, cytogenetics, molecular genetics and clinical 196 examination, which provide image-level ground truth labels that are much more robust.

With respect to explainability, DL is often referred to as a 'black box'.⁵⁰ The often elusive decision-197 198 making of neural networks substantially hampers interpretability and thus acceptance of DL models in 199 such high-risk applications as cancer diagnostics. Using OSM (among other methods of explainability⁵¹) not only enables internal proof-of-concept, but also provides additional information to 200 201 the human observer, as novel features that are important for prediction can be investigated that 202 otherwise would elude the human eye. Interestingly, our classifiers showed high attention for nuclei 203 not only of dysplastic cells, but also for cells that we did not deem to be morphologically suspicious 204 for dysplasia. Potentially, this alludes to a digital biomarker in MDS distinct from classical signs of 205 dysplasia. Future work will focus on correlating attention maps with genetic alterations and/or gene 206 expression in MDS. While certain molecular alterations have already been linked to certain morphologies, such as mutated SF3B1 in MDS with ringsideroblasts^{52,53}, CNNs can potentially be 207 used to identify novel gene-morphology links. For instance, Brück et al.⁵⁴ used CNNs on MDS bone 208 209 marrow core biopsies to predict mutations of TET2, spliceosome genes and monosomy 7. Further, Nagata et al.⁵⁵ previously demonstrated a link between MDS morphology (assessed by pathologists) 210 211 and genomic profiles. This suggests a starting point for CNNs to link gene alterations with specific 212 morphologies and may potentially lead to an image-based predictor of genetic profiles and 213 consequentially patient risk and outcome.

214	Our study is limited by several factors. As is the case for most recent studies of computer vision in
215	(hemato-)pathology, our analysis is based on retrospective data. While external validation confirmed
216	high classification accuracy, prospective validation is still warranted. In our study, we differentiated
217	only between AML, MDS, and healthy bone marrow donors in a binary way. Still, some dysplastic
218	morphologies can also be present to a certain degree in non-malignant disorders ⁵⁶ such as congenital
219	syndromes ⁵⁷ , nutritional deficiencies ^{58,59} , infectious disease ⁶⁰ , and drug- or toxin-mediated bone
220	marrow damage ^{61,62} . To increase routine applicability of our DL framework, future work will also
221	focus on acquiring image data from reactive and non-neoplastic specimen exhibiting bone marrow
222	dysplasia in order to make our classifier more versatile and applicable in clinical routine.
223	In summary, we have developed a DL framework trained on patient and donor samples, achieving
224	high accuracies in our internal test set and external validation set in distinguishing between MDS.

- AML, and healthy bone marrow donors.
- 226

227 List of Abbreviations

- 228 AML acute myeloid leukemia; BMS bone marrow smear(s); CNN convolutional neural net; DL
- 229 deep learning; MDS myelodysplastic neoplasm(s)

230

231 Acknowledgements

The authors are grateful to the Centre for Information Services and High-Performance Computing of the TUD Dresden University of Technology for providing its facilities for training and execution of deep learning models. This study was funded in part by Novartis Oncology. The funder had no role in conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.

237

238 Author Contributions

- 239 J-NE and JMM conceptualized the project. J-NE, FS, MEVG, KS, ASS, CR, UP, CP, TH, MB, and
- 240 JMM provided patient samples. J-NE, FS, MS, LR, and MEHG acquired BMS images. IS, TS, SR,
- and KW developed computer vision models. All authors analyzed and interpreted the data. J-NE wrote
- the initial draft. All authors approved the final version of the manuscript and agreed to be accountable
- for all aspects of the work.

244

245 Competing Interests

246 J-NE, TS, SR, and JMM are co-owners of Cancilico.

247

248 **References**

- 249 1 Cazzola M. Myelodysplastic Syndromes. N Engl J Med 2020; 383: 1358–1374.
- 2 Greenberg PL, Attar E, Bennett JM, Bloomfield CD, Borate U, De Castro CM *et al.* Myelodysplastic syndromes: clinical practice guidelines in oncology. *J Natl Compr Canc Netw* 2013; **11**: 838–874.
- Neukirchen J, Schoonen WM, Strupp C, Gattermann N, Aul C, Haas R *et al.* Incidence
 and prevalence of myelodysplastic syndromes: Data from the Düsseldorf MDS-registry.
 Leukemia Research 2011; **35**: 1591–1596.
- Cogle CR. Incidence and Burden of the Myelodysplastic Syndromes. *Curr Hematol Malig Rep* 2015; **10**: 272–281.
- 5 Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF *et al.* The 5th edition of
 the World Health Organization Classification of Haematolymphoid Tumours: Myeloid
 and Histiocytic/Dendritic Neoplasms. *Leukemia* 2022; **36**: 1703–1719.
- 6 Goasguen JE, Bennett JM, Bain BJ, Brunning R, Vallespi M-T, Tomonaga M *et al.*Dyserythropoiesis in the diagnosis of the myelodysplastic syndromes and other myeloid
 neoplasms: problem areas. *Br J Haematol* 2018; **182**: 526–533.
- Sasada K, Yamamoto N, Masuda H, Tanaka Y, Ishihara A, Takamatsu Y *et al.* Inter observer variance and the need for standardization in the morphological classification of
 myelodysplastic syndrome. *Leuk Res* 2018; **69**: 54–59.
- Valent P, Orazi A, Steensma DP, Ebert BL, Haase D, Malcovati L *et al.* Proposed
 minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS
 conditions. *Oncotarget* 2017; 8: 73483–73500.

270 9 Zhang L, Stablein DM, Epling-Burnette P, Harrington AM, Moscinski LC, Kroft S *et al.*271 Diagnosis of Myelodysplastic Syndromes and Related Conditions: Rates of Discordance
272 between Local and Central Review in the NHLBI MDS Natural History Study. *Blood*273 2018; **132**: 4370.

- Lee S-H, Erber WN, Porwit A, Tomonaga M, Peterson LC, International Council for
 Standardization In Hematology. ICSH guidelines for the standardization of bone marrow
 specimens and reports. *Int J Lab Hematol* 2008; **30**: 349–364.
- 277 11 Bain BJ, Clark DM, Wilkins BS. Bone Marrow Pathology. John Wiley & Sons, 2019.
- Bain BJ, Bailey K. Pitfalls in obtaining and interpreting bone marrow aspirates: to err is
 human. *J Clin Pathol* 2011; 64: 373–379.
- 13 Krizhevsky A, Sutskever I, Hinton GE. ImageNet classification with deep convolutional neural networks. In: *Proceedings of the 25th International Conference on Neural Information Processing Systems - Volume 1*. Curran Associates Inc.: Red Hook, NY, USA, 2012, pp 1097–1105.
- 14 Chan H-P, Samala RK, Hadjiiski LM, Zhou C. Deep Learning in Medical Image
 Analysis. *Adv Exp Med Biol* 2020; **1213**: 3–21.

15 Walter W, Haferlach C, Nadarajah N, Schmidts I, Kühn C, Kern W *et al.* How artificial
intelligence might disrupt diagnostics in hematology in the near future. *Oncogene* 2021;
40: 4271–4280.

- 16 Dhillon A, Verma GK. Convolutional neural network: a review of models, methodologies
 and applications to object detection. *Prog Artif Intell* 2020; 9: 85–112.
- Matek C, Krappe S, Münzenmayer C, Haferlach T, Marr C. Highly accurate
 differentiation of bone marrow cell morphologies using deep neural networks on a large
 image data set. *Blood* 2021; **138**: 1917–1927.
- 294 18 Choi JW, Ku Y, Yoo BW, Kim J-A, Lee DS, Chai YJ *et al.* White blood cell differential
 295 count of maturation stages in bone marrow smear using dual-stage convolutional neural
 296 networks. *PLoS One* 2017; **12**: e0189259.
- Kainz P, Burgsteiner H, Asslaber M, Ahammer H. Training echo state networks for
 rotation-invariant bone marrow cell classification. *Neural Comput Appl* 2017; 28: 1277–
 1292.
- Matek C, Schwarz S, Spiekermann K, Marr C. Human-level recognition of blast cells in
 acute myeloid leukaemia with convolutional neural networks. *Nat Mach Intell* 2019; 1:
 538–544.
- Putzu L, Caocci G, Di Ruberto C. Leucocyte classification for leukaemia detection using
 image processing techniques. *Artif Intell Med* 2014; 62: 179–191.
- Rodellar J, Alférez S, Acevedo A, Molina A, Merino A. Image processing and machine
 learning in the morphological analysis of blood cells. *Int J Lab Hematol* 2018; 40 Suppl
 1: 46–53.

308 23309310	Acevedo A, Merino A, Boldú L, Molina Á, Alférez S, Rodellar J. A new convolutional neural network predictive model for the automatic recognition of hypogranulated neutrophils in myelodysplastic syndromes. <i>Comput Biol Med</i> 2021; 134 : 104479.
311 24 312	Saraswat M, Arya KV. Automated microscopic image analysis for leukocytes identification: a survey. <i>Micron</i> 2014; 65 : 20–33.
 313 25 314 315 316 	Wu Y-Y, Huang T-C, Ye R-H, Fang W-H, Lai S-W, Chang P-Y <i>et al.</i> A Hematologist- Level Deep Learning Algorithm (BMSNet) for Assessing the Morphologies of Single Nuclear Balls in Bone Marrow Smears: Algorithm Development. <i>JMIR Med Inform</i> 2020; 8 : e15963.
317 26 318	Rezatofighi SH, Soltanian-Zadeh H. Automatic recognition of five types of white blood cells in peripheral blood. <i>Comput Med Imaging Graph</i> 2011; 35 : 333–343.
319 27 320	Mori J, Kaji S, Kawai H, Kida S, Tsubokura M, Fukatsu M <i>et al.</i> Assessment of dysplasia in bone marrow smear with convolutional neural network. <i>Sci Rep</i> 2020; 10 : 14734.
321 28 322 323	Fu X, Fu M, Li Q, Peng X, Lu J, Fang F <i>et al.</i> Morphogo: An Automatic Bone Marrow Cell Classification System on Digital Images Analyzed by Artificial Intelligence. <i>Acta Cytol</i> 2020; 64 : 588–596.
324 29 325 326	Eckardt J-N, Middeke JM, Riechert S, Schmittmann T, Sulaiman AS, Kramer M <i>et al.</i> Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. <i>Leukemia</i> 2022; 36 : 111–118.
327 30 328 329	Eckardt J-N, Schmittmann T, Riechert S, Kramer M, Sulaiman AS, Sockel K <i>et al.</i> Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. <i>BMC Cancer</i> 2022; 22 : 201.
330 31331332	Röllig C, Thiede C, Gramatzki M, Aulitzky W, Bodenstein H, Bornhäuser M <i>et al.</i> A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial. <i>Blood</i> 2010; 116 : 971–978.
 333 32 334 335 336 	Schaich M, Parmentier S, Kramer M, Illmer T, Stölzel F, Röllig C <i>et al.</i> High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial. <i>J Clin Oncol</i> 2013; 31 : 2094–2102.
337 33 338 339	Röllig C. Intermediate-dose cytarabine plus mitoxantrone versus standard-dose cytarabine plus daunorubicin for acute myeloid leukemia in elderly patients. <i>Ann Oncol</i> 2018; 29 : 973–978.
 340 34 341 342 343 	Röllig C, Serve H, Hüttmann A, Noppeney R, Müller-Tidow C, Krug U <i>et al.</i> Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial. <i>Lancet Oncol</i> 2015; 16 : 1691–1699.
344 35 345 346	Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M <i>et al.</i> International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. <i>Blood</i> 2022; 140 : 1200–1228.

- 36 Parmentier S, Kramer M, Weller S, Schuler U, Ordemann R, Rall G *et al.* Reevaluation of
 reference values for bone marrow differential counts in 236 healthy bone marrow donors. *Ann Hematol* 2020; **99**: 2723–2729.
- World Medical Association. World Medical Association Declaration of Helsinki: ethical
 principles for medical research involving human subjects. *JAMA* 2013; **310**: 2191–2194.
- 352 38 Swerdlow, SH, Campo, E, Harris, NL, Jaffe, ES, Pileri, SA, Stein, H *et al. WHO* 353 *Classification of Tumours of Haematopoietic and Lymphoid Tissues.*
- 354 https://publications.iarc.fr/Book-And-Report-Series/Who-Classification-Of-
- 355 Tumours/WHO-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017 (accessed 10 Nov2024)
- 356 2017 (accessed 19 Nov2024).
- 39 He K, Zhang X, Ren S, Sun J. Deep Residual Learning for Image Recognition. In: 2016 *IEEE Conference on Computer Vision and Pattern Recognition (CVPR)*. IEEE: Las
 Vegas, NV, USA, 2016, pp 770–778.
- 40 Xie S, Girshick R, Dollár P, Tu Z, He K. Aggregated Residual Transformations for Deep
 Neural Networks. In: 2017 IEEE Conference on Computer Vision and Pattern
 Recognition (CVPR). 2017, pp 5987–5995.
- 363 41 Zagoruyko S, Komodakis N. Wide Residual Networks. 2017.
 364 doi:10.48550/arXiv.1605.07146.
- Huang G, Liu Z, Maaten L van der, Weinberger KQ. Densely Connected Convolutional
 Networks. 2018. doi:10.48550/arXiv.1608.06993.
- 367 43 Zhang X, Zhou X, Lin M, Sun J. ShuffleNet: An Extremely Efficient Convolutional
 368 Neural Network for Mobile Devices. 2017. doi:10.48550/arXiv.1707.01083.
- 44 Iandola FN, Han S, Moskewicz MW, Ashraf K, Dally WJ, Keutzer K. SqueezeNet:
 AlexNet-level accuracy with 50x fewer parameters and <0.5MB model size. 2016.
 doi:10.48550/arXiv.1602.07360.
- 45 Deng J. ImageNet: A large-scale hierarchical image database. In: 2009 IEEE Conference
 on Computer Vision and Pattern Recognition 248–255. 2009
 doi:10.1109/CVPR.2009.5206848.
- 46 Akiba T, Sano S, Yanase T, Ohta T, Koyama M. Optuna: A Next-generation
 Hyperparameter Optimization Framework. In: *Proceedings of the 25th ACM SIGKDD International Conference on Knowledge Discovery & Data Mining*. Association for
 Computing Machinery, New York, NY, USA, 2010, pp 2623, 2631
- Computing Machinery: New York, NY, USA, 2019, pp 2623–2631.
- 47 Bain BJ. Diagnosis from the blood smear. *N Engl J Med* 2005; **353**: 498–507.
- 48 Lee N, Jeong S, Park M-J, Song W. Deep learning application of the discrimination of
 bone marrow aspiration cells in patients with myelodysplastic syndromes. *Sci Rep* 2022;
 12: 18677.
- 49 Kimura K, Tabe Y, Ai T, Takehara I, Fukuda H, Takahashi H *et al.* A novel automated
 image analysis system using deep convolutional neural networks can assist to differentiate
 MDS and AA. *Sci Rep* 2019; **9**: 13385.

- 50 Castelvecchi D. Can we open the black box of AI? *Nature* 2016; **538**: 20–23.
- Joshi G, Walambe R, Kotecha K. A Review on Explainability in Multimodal Deep Neural
 Nets. 2021. doi:10.48550/arXiv.2105.07878.
- Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M *et al.* SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring
 sideroblasts. *Blood* 2015; **126**: 233–241.
- SPapaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D *et al.* Somatic
 SF3B1 mutation in myelodysplasia with ring sideroblasts. *N Engl J Med* 2011; 365:
 1384–1395.
- 54 Brück OE, Lallukka-Brück SE, Hohtari HR, Ianevski A, Ebeling FT, Kovanen PE *et al.*Machine Learning of Bone Marrow Histopathology Identifies Genetic and Clinical
 Determinants in Patients with MDS. *Blood Cancer Discovery* 2021; 2: 238–249.
- Solution Set al. Machine
 Nagata Y, Zhao R, Awada H, Kerr CM, Mirzaev I, Kongkiatkamon S *et al.* Machine
 learning demonstrates that somatic mutations imprint invariant morphologic features in
 myelodysplastic syndromes. *Blood* 2020; **136**: 2249–2262.
- 56 Steensma DP. Dysplasia has A differential diagnosis: distinguishing genuine
 myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors. *Curr Hematol Malig Rep* 2012; 7: 310–320.
- 404 57 Iolascon A, Heimpel H, Wahlin A, Tamary H. Congenital dyserythropoietic anemias:
 405 molecular insights and diagnostic approach. *Blood* 2013; **122**: 2162–2166.
- 406 58 Huff JD, Keung Y-K, Thakuri M, Beaty MW, Hurd DD, Owen J *et al.* Copper deficiency
 407 causes reversible myelodysplasia. *Am J Hematol* 2007; **82**: 625–630.
- 408 59 Batata M, Spray GH, Bolton FG, Higgins G, Wollner L. Blood and bone marrow changes
 409 in elderly patients, with special reference to folic acid, vitamin B12, iron, and ascorbic
 410 acid. *Br Med J* 1967; 2: 667–669.
- 60 Sheikha A. Dyserythropoiesis in 105 patients with visceral leishmaniasis. *Lab Hematol*2004; 10: 206–211.
- 413 61 Michot F, Gut J. Alcohol-induced bone marrow damage. A bone marrow study in
 414 alcohol-dependent individuals. *Acta Haematol* 1987; **78**: 252–257.
- 415 62 Dusse LMS, Moreira AMB, Vieira LM, Rios DRA, Silva RMM e, Carvalho M das G.
 416 Acquired Pelger-Huët: what does it really mean? *Clin Chim Acta* 2010; **411**: 1587–1590.
- 417

418 Tables

419 Table 1. MDS patient characteristics

Parameter			
Ν	463		
Age in years, median (IQR)	66 (18-89)		
Sex, %			
Male	59		
Female	41		
MDS type (WHO 2022), %			
MDS-5q	10		
with SF3B1 mutation	0.1		
with TP53 mutation	0.1		
MDS biTP53	0.2		
MDS SF3B1	8.8		
MDS-LB	29.3		
MDS, hypoplastic	2.7		
MDS-IB1	15.6		
MDS-IB2	20		
MDS with fibrosis	1.3		
MDS/MPN-RS-T	0.5		
CMML-1	1.2		
CMML-2	9.8		
IPSS-R, %			
Very low risk	6.4		
Low risk	21.6		
Intermediate risk	38.7		
High risk	22.3		
Very high risk	10.9		
Blood count			
WBC in GPt/l, median (IQR)	3.58 (0.57-91.1)		
Hb in g/dl, median (IQR)	9.9 (4.4-15.6)		
Plt in GPt/l, median (IQR)	96 (3-1531)		
PB blasts in %, median (IQR)	0 (0-15)		
BM blasts in %, median (IQR)	5.5 (0-26.0)		

BM bone marrow, CMML-1/2 chronic myelomonocytic leukemia subgroup 1/2, Hb hemoglobin, MDS myelodysplastic neoplasm, MDS biTP53 MDS with biallelic TP53 inactivation, MDS-5q MDS with low blasts and isolated 5q deletion, MDS-IB1/2 MDS with increased blasts 1/2, MDS-LB MDS with low blasts, MDS/MPN-RS-T myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis, MDS-SF3B1 MDS with low blasts and SF3B1 mutation, N number, PB peripheral blood, Plt platelet count, WBC white blood cell count.

	MDS vs. hea	althy donors	MDS vs. AML	
DL architecture	Densenet-201		Squeezenet v1.1	
Accuracy	0.97791 [0.9561 - 0.9977]		0.98072 [0.9686 - 0.9904]	
	MDS	Healthy donors	MDS	AML
Precision	0.9973 [0.9948 - 1.0]	0.8547 [0.7121 - 0.9791]	0.97065 [0.9637 - 0.9967]	0.98118 [0.9565 - 0.9904]
	MDS	Healthy donors	MDS	AML
Recall	0.9775 [0.9507 - 0.9974]	0.9787 [0.9574 - 1.0]	0.98180 [0.9565 - 0.9906]	0.98030 [0.9616 - 0.9968]
ROCAUC	0.9708 [0.9241 - 0.9893]		0.9945 [0.98824 - 0.9984]	

426 Table 2. Test set performance for binary image-level classifications.

427 Brackets indicate 95% confidence intervals. AML acute myeloid leukemia, DL deep learning, MDS

428 myelodysplastic neoplasm, *ROCAUC* area-under-the-curve of the receiver-operating-characteristic.

	MDS (MLL cohort) vs. healthy donors		MDS (MLL cohort) vs. AML	
DL architecture	Densenet-201		Squeezenet v1.1	
Accuracy	0.9972 [0.9811 - 0.9963]		0.92104 [0.8905 - 0.9567]	
	MDS	Healthy	MDS	AML
Precision	0.9925 [0.9892 - 1.0]	0.9852 [0.9787 - 0.9957]	0.91418 [0.8880 - 0.9398]	0.94668 [0.8245 - 1.0]
	MDS	Healthy	MDS	AML
Recall	0.9970 [0.9940 - 0.9980]	0.9938 [0.9755 - 1.0]	0.97516 [0.9139 - 1.0]	0.80834 [0.7375 - 0.8667]
ROCAUC	0.9823 [0.9593 - 0.9972]		0.98552 [0.9746 - 0.9951]	

429 Table 3. Model performance on external validation set

430 Brackets indicate 95% confidence intervals. AML acute myeloid leukemia, MDS myelodysplastic

431 neoplasm, MLL Munich Leukemia Laboratory, ROCAUC area-under-the-curve of the receiver-

432 operating-characteristic.

433 **Figure Legends**

434 Figure 1: Performance of deep learning models for binary classifications delineating MDS, 435 AML, and healthy donors. The receiver-operating characteristic (ROC) with the corresponding area-436 under-the-curve (AUC) is depicted for the best performing models for each classification task. For 437 MDS vs. healthy donors, best results were achieved with Densenet-201 (A). For MDS vs. AML, best 438 results were achieved with Squeezenet (B). Internal cross-validation was performed with an 80:20 439 split. Individual run performance (Fold 1-5; graphs in light blue, orange, green, red, and purple) as 440 well as aggregate macro average performance (graph in dark blue) are reported. Only testing results 441 are reported.

442

Figure 2: External validation of deep learning models for binary classifications delineating MDS, AML, and healthy donors. The receiver-operating characteristic (ROC) with the corresponding area-under-the-curve (AUC) is depicted for the best performing models for the binary classifications MDS (MLL) vs. healthy donors (A) and MDS (MLL) vs. AML (B). Individual run performance (Fold 1-5; graphs in light blue, orange, green, red, and purple) as well as aggregate macro average performance (graph in dark blue) are reported.

449

450 Figure 3: Occlusion Sensitivity Mapping (OSM) highlights network attention for explainable 451 output interpretation. OSM iteratively blocks image areas from being evaluated by the deep learning 452 network. If an image area is highly important for classification, the network's performance will thus 453 drop substantially in the given iteration. Image areas that are of high importance for correct 454 classification can thereby be highlighted (high attention shown in red). A standard field of view of 455 bone marrow smears from MDS patients is shown in A, C, and E. The corresponding OSM is 456 displayed in B, D, and F, respectively. First, in a proof-of-concept fashion, the network focuses its 457 attention on cells and specifically on nuclei. It does not consider background, noise or smudge as 458 important for classification. Second, high attention is directed at erythropoietic and granulopoietic 459 cells as well as megakaryocytes.

Figure 1





Figure 2







0.2

0.8

1.0